Mortality was greater in levosimendan than in placebo subjects, but there was a nonsignificant trend to improved survival compared to dobutamine subjects (8) .
← all excerpts
Is Protein Kinase C Inhibition the Tip of the Iceberg in New Therapeutics for Acutely Decompensated Heart Failure?
1
—
—